The Journal of Hepatocellular Carcinoma is an international, peer-reviewed, open access journal.
The journal provides the international community with a platform for the dissemination and study of clinical, translational, and basic research findings in this rapidly developing field. Primary liver tumors, primarily hepatocellular carcinoma (HCC), are the third leading cause of cancer death worldwide, with around 750,000 new cases annually, and around 700,000 deaths. While 80% occurs in the developing world, the incidence is beginning to decline due to hepatitis B vaccination and developments in food hygiene; conversely, there is an increasing incidence in the developed world, partly due to metabolic syndrome, obesity and diabetes.
The journal welcomes original research manuscripts, reviews, clinical trial reports, expert opinions and commentaries relating to all aspects of HCC, spanning from basic laboratory research through to clinical and translational research.
Meta-analyses will no longer be considered for publication.
Specific topics covered by the journal include:
- cell signalling pathways
- molecular tumor classification and prognostication
- new drugs and other therapies
- new radiology approaches
- epidemiology, surveillance, and prevention
- psychosocial aspects and quality of life issues
The journal will consider case reports only if they make a valuable and original contribution to the literature. Study protocols are not suitable unless at least pilot or baseline data are provided.
When considering submission of a paper utilizing publicly available data, authors should ensure that such studies add significantly to the body of knowledge and that they are validated using the authors' own data through replication in an original sample.
Explore the most recently published articles